Conference on 1/31/2024

Antitrust, Regulation & the Next World Order

We are proud to support this upcoming event, organized and chaired by Cristina Caffarra, in Brussels. The conference will be available in person and online.


Event videos

Health Care Competition Conference

On October 26th, we held a conference to discuss current trends in competition policy in health care markets.

See Videos

Trial Transcripts

US v. Google

Are you following the most important tech monopoly trial of the century? Read transcripts of the proceedings on our website.

Read More

Discover the Benefits of a Subscription

Our content provides subscribers with unique insight and breaking news regarding the most complex mergers and regulatory situations around the world.


The Capitol Forum Advantage

Our work combines cutting edge breaking news with in-depth analysis to better inform readers how policy and regulation affects market competition.

Learn More

The Capitol Forum Community

Our editorial team reconstructs the policy process to yield market insight for a community of subscribers including government regulators, lawyers, investors, and non-profits.

Learn More


View all


View all


We are an investigative news organization providing our subscribers with detail-oriented reporting on antitrust, merger control, corporate investigations, and energy issues.



Karl A. Racine - Former D.C. Attorney General

“I appreciate the helpful work done by The Capitol Forum. It’s one of the sources I turn to for information about what activity is out there not only in the antitrust space, but also in the consumer protection world.”

Melissa H. Maxman - Partner, Cohen & Gresser

“I have become an avid reader of The Capitol Forum because it provides timely in-depth news and analysis of the myriad legal, business, legislative and political factors affecting business developments. I always come away with fresh perspectives that help me advise my clients about current issues.”

Professor Thomas J. Horton - The University of South Dakota School of Law

“I eagerly read every report from The Capitol Forum and have great admiration for its reporters and editors. I find it to be the single best source of up-to-the-minute coverage and objective in-depth analysis of cutting-edge antitrust news and other critical competition-related developments.”

Barry Nigro - Partner and Antitrust Chair, Fried Frank

“The Capitol Forum’s news and analysis is spot on and reflects a perfect mix of investigative reporting, independent research, and expert opinion.”

Bert Foer - Former President, American Antitrust Institute

“The Capitol Forum provides an always interesting and sometimes surprising look under the hood about pending antitrust activities.”

Barry Lynnn - Citizens Against Monopoly

“The Capitol Forum is the only team covering this incredibly important beat. Better yet, their work is deeply intelligent, influential, and almost always right.”

Allen Grunes - Co-Founder, Konkurrenz Group

“The Capitol Forum consistently provides timely and sophisticated news and analysis of important M & A transactions. It’s the real deal!”

David Witkin - Beryl Capital Management

“The Capitol Forum has been an indispensable resource for me in analyzing regulatory risk affecting companies in my portfolio or watch list.”


View all


View all
Thank you for subscribing to our newsletter


View all

SPECIAL REPORT: Coordination Out Loud

Analysis of select corporate transcripts through the lens of Joseph Harrington’s landmark paper, “Collusion in Plain Sight: Firms’ use of Public Announcements to Restrain Competition.”

Sep 07, 2023 Read Now >

SPECIAL REPORT: Johnson & Johnson’s Remicade

Get an inside view of the biologics market, where rebate schemes appear to drive market share. You’ll learn how a complex system supports sluggish biosimilar uptake and other types of anticompetitive conduct. 

Sep 05, 2023 Read Now >

SPECIAL REPORT: Exclusive Drug Dealing

The Capitol Forum has recently published a special report with an extract of reporting that has been done analyzing price, market share and generic formulary exclusion data to spot anticompetitive conduct.

May 11, 2023 Read Now >